Related references
Note: Only part of the references are listed.Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
Antonio Passaro et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
Alberto Pavan et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Alfredo Addeo et al.
CANCER TREATMENT REVIEWS (2021)
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Ilaria Attili et al.
LUNG CANCER (2021)
The Promising Evolution of Targeted Therapeutic Strategies in Cancer
Solange Peters et al.
CANCER DISCOVERY (2021)
Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro et al.
NATURE CANCER (2021)
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
Elisabetta Zulato et al.
BRITISH JOURNAL OF CANCER (2020)
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data
Antonio Passaro et al.
CANCER TREATMENT REVIEWS (2020)
Understanding EGFR heterogeneity in lung cancer
Antonio Passaro et al.
ESMO OPEN (2020)
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
Ilaria Attili et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
Caterina Fumagalli et al.
BREAST CANCER RESEARCH (2020)
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
Youjin Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma
Jake June-Koo Lee et al.
CELL (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2018)
The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics
Caterina Fumagalli et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells
Marzia Del Re et al.
STEM CELLS (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)
Dara L. Aisner et al.
CLINICAL CANCER RESEARCH (2018)
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
June-Koo Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
Paul A. VanderLaan et al.
LUNG CANCER (2017)
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Catherine Labbe et al.
LUNG CANCER (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Modeling Tumor Clonal Evolution for Drug Combinations Design
Boyang Zhao et al.
TRENDS IN CANCER (2016)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
